Intravenous iron in patients with heart failure and reduced ejection fraction (HFREF) plus iron deficiency: Effects upon phosphate and FGF23 metabolism
Phase of Trial: Phase II
Latest Information Update: 26 Dec 2017
Price : $35 *
At a glance
- Drugs Ferric carboxymaltose (Primary)
- Indications Chronic heart failure; Iron deficiency anaemia
- Focus Therapeutic Use
- Acronyms Iron Turtle
- 31 Aug 2018 Biomarkers information updated
- 05 Dec 2017 Status changed from recruiting to completed.
- 18 Apr 2017 Status changed from not yet recruiting to recruiting.